Listed Funds Trust. Holdings as of Jun 30, 2026, from Form N-PORT.
Share of net assets at the report date, for the whole fund across all share classes.
| Holding | Weight | Value | Shares or units |
|---|---|---|---|
| Eli Lilly & CoLLY | 18.46% | $3.52M | 2,936 |
| US BANK MMDA - USBGFS 7Cash or money market | 9.19% | $1.75M | 1,752,681 |
| AbbVie IncABBV | 8.85% | $1.69M | 6,712 |
| Novartis AGNVS | 6.89% | $1.31M | 8,388 |
| Johnson & JohnsonJNJ | 5.59% | $1.07M | 4,200 |
| Alkermes PLC | 5.53% | $1.05M | 20,132 |
| AstraZeneca PLC | 4.98% | $950.94K | 5,015 |
| Ionis Pharmaceuticals IncIONS | 4.53% | $864.58K | 10,904 |
| Bristol-Myers Squibb CoBMY | 4.42% | $843.79K | 14,644 |
| Merck & Co IncMRK | 3.96% | $754.55K | 5,872 |
| Amgen IncAMGN | 3.91% | $746.69K | 2,062 |
| Alnylam Pharmaceuticals IncALNY | 3.42% | $652.63K | 2,168 |
| Biogen IncBIIB | 3.09% | $588.98K | 2,726 |
| Pfizer IncPFE | 2.86% | $545.36K | 22,648 |
| GSK PLCGSK | 2.71% | $516.13K | 9,846 |
| CRISPR Therapeutics AG | 2.64% | $503.30K | 9,228 |
| Regeneron Pharmaceuticals IncREGN | 2.06% | $392.83K | 630 |
| Beam Therapeutics IncBEAM | 1.51% | $287.88K | 8,388 |
| Galectin Therapeutics IncGALT | 1.14% | $217.93K | 46,968 |
| Intellia Therapeutics IncNTLA | 1.12% | $212.92K | 12,584 |
| Sandoz Group AG | 0.80% | $152.02K | 1,680 |
| Replimune Group IncREPL | 0.73% | $139.30K | 12,584 |
| Vanda Pharmaceuticals IncVNDA | 0.73% | $138.61K | 22,648 |
| Haleon PLCHLN | 0.60% | $114.84K | 12,309 |
| Lantern Pharma IncLTRN | 0.55% | $104.93K | 25,164 |
| Editas Medicine IncEDIT | 0.47% | $89.68K | 27,680 |
| GE HealthCare Technologies IncGEHC | 0.28% | $53.77K | 840 |
| Bicycle Therapeutics PLCBCYC | 0.28% | $53.36K | 12,584 |
| Viatris IncVTRS | 0.26% | $49.58K | 3,122 |
| Allogene Therapeutics IncALLO | 0.18% | $34.89K | 16,776 |
| Pacific Biosciences of CaliforPACB | 0.09% | $16.91K | 10,068 |
| Decoy Therapeutics IncDCOY | 0.00% | $149 | 21 |
| Pathos AI Inc | 0.00% | $0 | 23,992 |
Holdings from the fund's latest Form N-PORT; expense ratio (net of fee waivers) from the risk/return summary of its prospectus; fund type from Form N-CEN. Prices are end-of-day closes adjusted for splits; total return also reinvests distributions.